I have just run a few searches on the Fù kāngrén (阜康仁) company and I have some questions regarding your research.
You've stated "Self claming on frontal R&D research, which i couldnt find any detail about it."
With the understanding that the company is not listed, I would not expect to see their name published over the net regarding products that they distribute however the search below produces >5000 search results and every result I've checked appears relevant to the company: https://www.google.com.au/search?q=...BMT_8QW5hLzQAg&start=10&sa=N&biw=1242&bih=579
Going back to 1999, these include products, hiring, partnering, government validations, projects, R&D hiring, R&D indications etc.
& "Smaller cap than cellmid."
How did you draw conclusion on the companies market capitalisation given it is currently an unlisted company?
If you don't mind my asking, can you type/read chinese?
If yes, could you advise where I'm going wrong with my search?
-----------------
Below is a good write up I found on the development & R&D side of the business (from a chinese R&D job ad): 北京阜康仁生物制药科技有限公司
Beijing Ji Kangren Bio-pharmaceutical Technology Co., Ltd.
Brief
Corporate Profile
Beijing Ji Kangren Bio-pharmaceutical Technology Co., Ltd. is an innovative company specializing in the research and development of new drugs. The company was founded in 2000 and was formally established in 2002. The headquarters is located in Beijing Fengtai Science and Technology Park. Due to the company's development and growth at the end of 2014, the company moved to No. 30, Venus Road, Daxing District. Pei Kangren has been committed to the research and development of innovative drugs for many years and has accumulated rich experience and resources and is at the leading level in the field of innovative drugs. Since 2002, the company has been continuously certified as a "high-tech enterprise in Beijing" and a "national high-tech enterprise". It has also won the "Biopharmaceutical Laboratory of Beijing International Business Incubation Center", "Patented Engine Patent Pilot Enterprise in Zhongguancun Science Park," and " "Beijing Fengtai Science Park Sustained-release Formulation Platform" and other related honors.
Organization structure: The organization structure of
Kang Kangren is clear and the labor division is clear. There are three major experimental departments in the synthesis department, the preparation department, and the analysis department. They are responsible for the development of new drugs, and the information department, patent department, review department, and marketing department are responsible for new medicines.Research, reporting, and promotion services, among other departments, are responsible for company-related research and other related matters. As a whole, a very stringent new drug development model has been formed.
The research and development team
currently has a total of 105 frontline stafffor product development, including more than 60% of postgraduates or above. Bachelor degree or above accounted for more than 90%. The team has extensive experience in the development of state-level Class III new drugs and innovative drugs. A technologically advanced team in the domestic R&D industry.
In order to better develop the cause of new drug research and development, Ji Kangren has established close R&D cooperation relationships with a number of well-known research institutes in China. For example, he has established analysis of biological products, small molecule compounds, and pharmaceuticals with the Tianjin University School of Pharmacy. The close cooperation between Tsinghua University and the Department of Chemistry and the Department of Chemical Engineering of Tsinghua University established a close cooperation relationship on the development of nucleosides and peptides. In addition, Ji Kangren and the Capital Medical University, Peking University Medical College, and the Academy of Military Medical Sciences have also established research institutes. Cooperation, the establishment of student practice bases, and further broaden the company's scientific research resources and foreign cooperation.
Research equipment
The total scientific research area of Ji Kangren is nearly 3,000 m2. Each laboratory is equipped with small-scale test and pilot-plant equipment to meet the requirements of each phase of new drug development. The analysis center is equipped with 20 imported liquid chromatographs (HPLC) and 1 gas chromatograph (GC). , atomic absorption spectrophotometer 1 set, evaporative light scattering detector 1 set, Shimadzu differential detector 1 set, UV spectrophotometer 2 sets, polarimeter 1 set and a large number of scientific research equipment, at the same time, we and the analysis center of Peking University, Capital Medical University established a wide range of business partnerships and expanded scientific research resources. At present, the company is still actively expanding the company's R&D scale and resources. In 2010, Fukangren New Drug Synthesis Base was established in Daxing District. The base is equipped with advanced and comprehensive R&D equipment to ensure the smooth progress of the new drug synthesis project.
The following is a summary of the company's laboratory
synthesis room:
Preparation room:
Analysis room:
Research field
Kang Kangren is committed to the development of new drugs at home and abroad, the business areas involved include the following aspects
1, a difficult generics: a certain technology Difficulties of drug imitation
2, non-patent drugs grab imitation, high imitation
3, foreign research and introduction of marketed products
4, innovative drugs: imitation drugs with independent intellectual property rights
5, new preparations: sustained-release preparation technology, difficult to drug Formulations and fat emulsions
6, industrialization of synthetic processes undertaken
7, technological improvement of major synthetic process projects
8, new business establishments, workshop business consultations
9, topic selection project business consultations
10, patent affairs business consulting and
foreign cooperation
domestic cooperation
On the basis of independent innovation, Ji Kangren also extensively collaborates with R&D units and manufacturing companies at home and abroad to form a technology innovation platform for information sharing. New technology innovation projects are continuously launched, providing rich materials for the company's high-end technology research and development. . Currently, Kang Kangren has broadened its research and development resources, and has established extensive and in-depth business with several well-known universities and more than one hundred manufacturers in China. There are several scientific research institutions such as Tsinghua University, Tianjin University School of Pharmacy, Peking University, and Military Academy of Sciences. long term partnership. Among them, the key cooperation institutions are Tsinghua University Small Molecular Laboratory, Peptide Laboratory, Polymer Laboratory; Tianjin University School of Pharmacy Small Molecular Laboratory, Biological Products Laboratory.
In addition, it has cooperated with hundreds of well-known domestic pharmaceutical companies, including Jiangzhong Pharmaceutical, Renhe Group, Jimin Credible, Xinhua Pharmaceutical, Xinbang Pharmaceutical, Nuojin Pharmaceutical, Hongqi Pharmaceutical, Shuangcheng Pharmaceutical, and Sihuan Kebao. , Procter & Gamble, Chongqing Corey, Zhuhai Federation, Luzhou Pharmaceutical, Shijiazhuang Group, Sichuan Baili, Shanghai Xinyi, Zhuhai Tongyi, Guangdong Bangmin, Shengjitang Pharmaceutical, Wanglaoji Pharmaceutical, Baiyunshan Pharmaceutical, Yuekang, Three well-known pharmaceutical companies such as Sanjing, Buchang, Zhendong, Jianfeng, Jinling, Guangyao, and Ma Yinglong. If international cooperation wants to make compulsory drugs, we must take the path of internationalization. The company attaches great importance to international cooperation. The
following is the
IPI of foreign institutions and companies that have established a cooperative relationship. It is affiliated with the famous University of Bradford in the UK. It is the largest research institute in the UK and Europe that applies artificial intelligence and computer simulation technology to the development of new drugs. one. It is also an industrial cooperation center designated by the British government. Experienced mainly in sustained-release preparations and infusible medicines
Kang Kangren has reached several agreements with it to develop high-end formulation technologies. The
Toronto Institute of Pharmaceutical Technology (TIPT) is North America's top pharmaceutical education, technology and research institution. All of Canada's pharmaceutical industry licenses are issued by the college; they are known for their excellence and pragmatism in medical technology education and training. Its long-term release agent has rich experience in technology and experience in product registration in European and American markets.
FITZROY PARTNERS LIMITED is a professional technology company dedicated to the life sciences and bio-industry. It is committed to investing in bio-pharmaceuticals and provides bio-pharmaceutical technology consulting services to domestic and foreign investors and partners. The company's investment series have entered clinical research in Europe and the United States, can be introduced domestically, and listed in the country. Its founder ALAN is a famous pharmacologist and financier.
Pei Kangren has established a stable cooperative relationship with the company in medical information consultation and drug import.
The German company HH (HH) is committed to the development and production of new drug delivery systems, new packaging models, and special pharmaceutical equipment. Ren Fukang has reached an agreement with the company, the introduction of many advanced technology equipment and
intellectual property rights
in Beijing patented engine unit
after a long period of exploration and precipitation, Ren Fukang achieve patent protection, research and development of new compounds, new drug development and formulation technology of traditional Chinese medicine Diversified development. In terms of intellectual property protection, the company currently has nearly 600 varieties of intellectual property rights, of which Jin Duofuwei has applied for international patents, and there are 10 pending international patent varieties; there are still 60 in the research and development projects. The remaining patents are being tested and are expected to be reported by the end of the year. At present, the company has obtained nearly 10 invention patents and has obtained a patent for invention. More than 10 types of innovative new drugs with independent intellectual property rights have entered the new drug application stage.
Development Philosophy
Since its inception, Kang Kangren has been pursuing the faith of "sincere service and scientific innovation." It has accumulated a group of outstanding corporate pioneers, and the team has sincerely cooperated and dared to innovate. All employees of the company are developing the company into an international innovation. Type of drug research institutions and work hard together. We are responsible for the development of the national pharmaceutical industry and the improvement of the national drug use. Try to get rid of the confusion of generic drugs as soon as possible and achieve a qualitative leap in the transformation of innovative drugs.
Kang Kangren is growing and developing, I believe we will do better......!
Beijing Ji Kangren Biopharmaceutical Technology Co., Ltd. welcomes you to join! ! !
CDY Price at posting:
53.0¢ Sentiment: Buy Disclosure: Held